Accelagen Pty Ltd Revenue and Competitors
Employee Data
- Accelagen Pty Ltd has 56 Employees.
- Accelagen Pty Ltd grew their employee count by 60% last year.
Accelagen Pty Ltd's People
Name | Title | Email/Phone |
---|
Accelagen Pty Ltd Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $95.5M | 616 | -23% | N/A | N/A |
#2 | $34.7M | 224 | N/A | N/A | N/A |
#3 | $14.7M | 95 | -5% | N/A | N/A |
#4 | $15.8M | 102 | 6% | N/A | N/A |
#5 | $16.9M | 109 | 7% | N/A | N/A |
#6 | $22.5M | 145 | 4% | N/A | N/A |
#7 | $19.5M | 126 | -4% | N/A | N/A |
#8 | $10.4M | 67 | -29% | N/A | N/A |
#9 | $9.7M | 84 | -14% | $412.3M | N/A |
#10 | $24.2M | 156 | 2% | N/A | N/A |
What Is Accelagen Pty Ltd?
o Accelagen is a full-service Australian Bio-pharmaceutical and Medical Device Development Organisation. We provide high quality regulatory affairs and clinical research services globally, with a level of professionalism and dedication that always exceeds our clients’ expectations.\no Based in Melbourne, our expert team works with clients around the world. Using in-depth knowledge of therapeutic areas and experience with design/execution of clinical trials, together with a dedicated service to the evolution of new technologies, we strive to make a difference in everything we do.\no Accelagen can also support organisations with strategic alliances to expert partners through all stages of a products lifecycle.\no Importantly, our team operates with a strong commitment to bring to life our company values each day – ultimately aiming to be the clinical research and regulatory affairs partner of choice.
keywords:N/AN/A
Total Funding
56
Number of Employees
N/A
Revenue (est)
60%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $11.7M | 59 | 4% | N/A |
#2 | $13.9M | 70 | 4% | N/A |
#3 | $7.5M | 80 | 5% | N/A |
#4 | $17.4M | 83 | 1% | N/A |
#5 | $17.6M | 98 | 23% | N/A |